CSIMarket
 
Zevra Therapeutics Inc   (ZVRA)
Other Ticker:  
 
 
Price: $4.5700 $0.05 1.106%
Day's High: $4.63 Week Perf: -4.19 %
Day's Low: $ 4.46 30 Day Perf: -23.19 %
Volume (M): 109 52 Wk High: $ 7.28
Volume (M$): $ 500 52 Wk Avg: $5.23
Open: $4.52 52 Wk Low: $3.89



 Market Capitalization (Millions $) 162
 Shares Outstanding (Millions) 35
 Employees -
 Revenues (TTM) (Millions $) 27
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 0

Zevra Therapeutics Inc
Zevra Therapeutics Inc is a pharmaceutical company that focuses on developing innovative and effective treatment options for various medical conditions. They are dedicated to advancing medical science through research and development of novel therapeutics. The company aims to address unmet medical needs and improve the lives of patients by bringing forward safe and reliable therapies. Zevra Therapeutics Inc aims to collaborate with healthcare professionals, patients, and partners to bring their products to market and make a positive impact in the healthcare industry.


   Company Address: 1180 Celebration Boulevard, Suite 103 Celebration 34747 FL
   Company Phone Number: 939-3416   Stock Exchange / Ticker: NASDAQ ZVRA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Zevra Therapeutics Secures Promising Future Through $100M Credit Facility for Rare Disease Solutions

Published Wed, Apr 10 2024 11:30 AM UTC

Zevra Therapeutics Secures Up to $100 Million in New Credit Facility to Advance Rare Disease Therapeutics
Celebration, Fla. - Zevra Therapeutics, a leading rare disease therapeutics company, announced today that it has successfully refinanced its existing debt by securing a new credit facility. The credit facility, provided by prominent biotech investors Perceptive Advi...

Zevra Therapeutics Inc

Headline:

The financial results of Zevra Therapeutics Inc. for the fiscal year ending December 31, 2023, show a significant increase in revenue, with a staggering 469.944% year-on-year growth to $13.22 million. This growth is impressive and indicates a strong demand for the company's products or services. However, the company also experienced diminishing returns with a net deficit of $-0.39, which is a cause for concern.
Despite the net deficit, there are positive signs for the company. The accounts receivable have increased, suggesting rising demand for their products. Additionally, Zevra announced a deficit of $-46.05 million and revenue of $27.46 million for the fiscal year 2023, showing growth in both areas compared to the previous year.

Clinical Study

Zevra Therapeutics on the Cusp of a Breakthrough: KP1077 Shows Potential in Phase 2 Clinical Trials for Idiopathic Hypersomnia (IH)

Published Tue, Mar 26 2024 8:30 PM UTC

In development-stage biopharmaceutical industry, every new drug discovery and validation stands as a potential breakthrough for patients struggling with various health concerns - often unmet medical conditions. One such breakthrough announcement comes from Zevra Therapeutics regarding their Phase 2 Clinical Trials for KP1077, a novel treatment candidate for Idiopathic Hypers...

Product Service News

Zevra Therapeutics Progresses with FDA Resubmission of Novel Niemann-Pick Disease Type C Treatment

Published Wed, Dec 27 2023 12:30 PM UTC

Resubmission of the New Drug Application (NDA) for arimoclomol, an experimental therapeutic agent aimed at combating Niemann-Pick disease type C (NPC), has been announced by Zevra Therapeutics, Inc., a leading pharmaceutical organization specializing in the development of treatments for rare diseases. The resubmission, placed with the U.S. Food and Drug Administration (FDA),...

Zevra Therapeutics Inc

Zevra Therapeutics Inc's Major Pharmaceutical Preparations Company Faces Escalating Deficit during the July to September 2023 Financial Interval

Zevra Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the July to September 30, 2023 financial interval. The company experienced an increase in the shortfall per share, reporting $-0.40 compared to $-0.19 the previous year. Additionally, the company's revenue grew moderately by 0.731% to $2.90 million from $2.87 million in the same reporting period a year before. However, sequentially, the revenue tumbled by -65.821% from $8.47 million.
While Zevra Therapeutics Inc's revenue growth has been lower than that of the overall major pharmaceutical preparations industry, it is important to note that the company's top-line gain fell short by only 1.86% compared to the same period a year ago.






 

Zevra Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Zevra Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Zevra Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com